Back to home » Treatment News
 September 28, 2007
|
Past Lexiva Treatment May Reduce Benefit From Prezista
A recent study reported by AIDSmap has found that some people who have developed drug resistance to the protease inhibitor (PI) Lexiva (fosamprenavir) may have a reduced benefit from another PI, Prezista (darunavir).
|
|
|
September 27, 2007
|
Ban on European Viracept Sales Lifted
The European Medicines Agency (EMEA) has announced that it is lifting its recent ban on the sale of Viracept (nelfinavir) in Europe, according to the Associated Press.
|
|
|
| September 26, 2007
|
| September 25, 2007
|
September 24, 2007
|
Maraviroc Gets EU Approval
Pfizer Inc announced today that the European Commission has approved the antiretroviral drug maraviroc for treatment-experienced patients in the European Union (EU).
|
|
|
September 21, 2007
|
48-Week Selzentry Data Show Promise for Drug-Resistant HIV
Forty-eight weeks of therapy with Selzentry, combined with an optimized background regimen (OBR), is associated with greater viral load reductions and CD4 count increases compared with placebo among HIV-positive patients with limited treatment options due to drug resistance.
|
|
|
September 20, 2007
|
Selzentry Treatment Failure: The Impact of Tropism Changes
Approximately two thirds of patients participating in Phase III studies of Pfizer’s Selzentry (maraviroc) who experience treatment failure have HIV that has switched its tropism—a shift in the cellular receptors it uses to infect CD4s.
|
|
|
HIV Prevalence Declines in Pregnant Women in Zimbabwe
Of a new study presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy in Chicago (ICAAC) this week, AIDSmap reports that the percentage of pregnant women who tested positive at a Zimbabwe hospital dropped by 41 percent between 1999 and 2007.
|
|
|
September 19, 2007
|
IL-2 May Delay Need for Antiretroviral Treatment
An intriguing study suggests that periodic injections with interleukin-2 (IL-2) may allow HIV-positive patients to keep their CD4 counts high and postpone their need to begin antiretroviral therapy.
|
|
|
September 18, 2007
|
Heart Disease Risk Remains in Absence of HIV Treatment
There is growing evidence to suggest that untreated HIV infection may be a bigger threat to heart health than the lipid-raising effects of antiretroviral therapy. New data reported at the 47th ICAAC may explain help explain why this is.
|
|
|
September 17, 2007
|
High Risk of Peripheral Artery Disease in HIV
Not only do HIV-positive people face an increased risk of heart attacks and strokes due to clogging of the major blood vessels, but they may also be more likely to suffer from peripheral artery disease (PAD), which can affect other parts of the body.
|
|
|
Lexiva and Kaletra Comparable in Long-Term Study
New data reported at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Chicago suggest that Norvir (ritonavir)-boosted Lexiva (fosamprenavir) is similar to Kaletra (ritonavir-boosted lopinavir) in terms of long-term safety and effectiveness.
|
|
|
September 14, 2007
|
Skin Test Predicts Control of HPV
A new study shows that a simple skin-prick test may be useful in helping HIV-positive women determine if their immune systems are strong enough to control cancer-causing human papilloma virus (HPV) infection.
|
|
|
September 13, 2007
|
More Reports on Kidney Stones With Reyataz
A French study, published in the September 12 issue of Clinical Infectious Diseases, mirrors another report from the United States suggesting that kidney stones may be a side effect of the protease inhibitor Reyataz.
|
|
|
| September 12, 2007
|
September 11, 2007
|
HIV Damages Brain Despite Treatment
HIV treatment may not fully protect the brain or eliminate the risk of impaired brain functioning, according to a new study published in the September issue of AIDS and reported today by AIDSmap.
|
|
|
September 10, 2007
|
High-Fat Diets Affect Disease Progression
Scientists have added another strike against high-fat diets. A recent animal study in the Journal of Infectious Diseases suggests that a diet high in saturated fat and cholesterol may accelerate HIV disease progression.
|
|
|
| September 07, 2007
|
September 06, 2007
|
Isentress Recommended for FDA Approval
As widely reported yesterday, an advisory committee to the FDA has unanimously voted to recommend approval for Isentress—the first of a new class of antiviral drug known as an integrase inhibitor—for use in people who’ve developed resistance to other drugs.
|
|
|
September 05, 2007
|
Promising New Nuke, Apricitabine
A new drug in development, apricitabine (ATC), may have moved another step closer toward inclusion in the arsenal of drugs approved to fight HIV.
|
|
|
| September 04, 2007
|
|
|
Have news about HIV? Send press releases, news tips and other announcements to news@poz.com. |
|
  March 2010
February 2010
January 2010
December 2009
November 2009
October 2009
September 2009
August 2009
July 2009
June 2009
May 2009
April 2009
March 2009
February 2009
January 2009
December 2008
November 2008
October 2008
September 2008
August 2008
July 2008
June 2008
May 2008
April 2008
March 2008
February 2008
January 2008
December 2007
November 2007
October 2007
September 2007
August 2007
July 2007
June 2007
May 2007
April 2007
March 2007
February 2007
January 2007
December 2006
November 2006
October 2006
September 2006
August 2006
July 2006
June 2006
May 2006
April 2006
February 2006
|
Peter Staley asks Dr. Sharon Walmsley what women need to know about HIV and antivirals, and gender differences needing more research.
Peter Staley asks Dr. Joe Eron about the latest data on soon-to-be-approved Isentress and an entry inhibitor you might inject just once every other week.
Peter Staley asks Dr. Joe Eron about the good news on a challenging drug -- newly-approved Selzentry -- and the very potent new protease inhibitor, Prezista.
Peter Staley interviews Jules Levin, an activist and survivor of hepatitis C and HIV coinfection, about the latest in HCV treatment and prevention.
Peter Staley talks with Matt Sharp about his activism, his new regimen, and his facial lipo fix.
